BIOMERIEUX (BIM.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:BIM - FR0013280286 - Common Stock
BIM.PA Key Statistics, Chart & Performance
The current stock price of BIM.PA is 107.1 EUR. In the past month the price decreased by -0.46%. In the past year, price increased by 4.9%.
BIM.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 2M6.DE | MEDTRONIC PLC | 17.7 | 108.95B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 18.42 | 49.67B | ||
| PHIA.AS | KONINKLIJKE PHILIPS NV | 15.36 | 21.90B | ||
| PHI1.DE | KONINKLIJKE PHILIPS NV | 15.32 | 21.84B | ||
| OBCK.DE | OTTOBOCK SE & CO KGAA | 145.85 | 4.39B | ||
| AFX.DE | CARL ZEISS MEDITEC AG - BR | 23.73 | 3.63B | ||
| DIA.MI | DIASORIN SPA | 19.24 | 3.56B | ||
| DRW3.DE | DRAEGERWERK AG - PREF | 10.52 | 1.27B | ||
| DRW8.DE | DRAEGERWERK AG | 9.24 | 1.12B | ||
| ELN.MI | EL.EN. SPA | 20.44 | 1.05B | ||
| EUZ.DE | ECKERT & ZIEGLER SE | 23.15 | 955.98M | ||
| GVS.MI | GVS SPA | 42.11 | 716.99M |
Related stock screener links
About BIM.PA
Company Profile
bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The company is headquartered in Craponne, Auvergne-Rhone-Alpes and currently employs 14,754 full-time employees. The company went IPO on 2004-06-07. The firm designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The firm also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.
Company Info
BIOMERIEUX
376, chemin de l'Orme
Craponne AUVERGNE-RHONE-ALPES FR
Employees: 14451
Phone: 33478872000
BIOMERIEUX / BIM.PA FAQ
What does BIOMERIEUX do?
bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The company is headquartered in Craponne, Auvergne-Rhone-Alpes and currently employs 14,754 full-time employees. The company went IPO on 2004-06-07. The firm designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The firm also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.
Can you provide the latest stock price for BIOMERIEUX?
The current stock price of BIM.PA is 107.1 EUR. The price increased by 0.56% in the last trading session.
Does BIOMERIEUX pay dividends?
BIOMERIEUX (BIM.PA) has a dividend yield of 0.85%. The yearly dividend amount is currently 0.85.
What is the ChartMill rating of BIOMERIEUX stock?
BIM.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Should I buy BIM stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BIM.PA.
When does BIOMERIEUX (BIM.PA) report earnings?
BIOMERIEUX (BIM.PA) will report earnings on 2026-03-05, after the market close.
Can you provide the ownership details for BIM stock?
You can find the ownership structure of BIOMERIEUX (BIM.PA) on the Ownership tab.
BIM.PA Technical Analysis
BIM.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to BIM.PA. While BIM.PA has a great health rating, its profitability is only average at the moment.
BIM.PA Financial Highlights
Over the last trailing twelve months BIM.PA reported a non-GAAP Earnings per Share(EPS) of 3.86. The EPS decreased by -8.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 9.17% | ||
| ROA | 7.04% | ||
| ROE | 9.61% | ||
| Debt/Equity | 0.09 |
BIM.PA Forecast & Estimates
17 analysts have analysed BIM.PA and the average price target is 126.31 EUR. This implies a price increase of 17.94% is expected in the next year compared to the current price of 107.1.
For the next year, analysts expect an EPS growth of 16.34% and a revenue growth 5.16% for BIM.PA